Cargando…
Effective inhibitors of the essential kinase PknB and their potential as anti-mycobacterial agents
PknB is an essential serine/threonine kinase of Mycobacterium tuberculosis with possible roles in a number of signalling pathways involved in cell division and metabolism. We screened a library of >50,000 compounds for inhibitors of the in vitro phosphorylation of GarA (Rv1827) by PknB and identi...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Churchill Livingstone
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3158675/ https://www.ncbi.nlm.nih.gov/pubmed/21482481 http://dx.doi.org/10.1016/j.tube.2011.03.005 |
_version_ | 1782210387680165888 |
---|---|
author | Lougheed, Kathryn E.A. Osborne, Simon A. Saxty, Barbara Whalley, David Chapman, Tim Bouloc, Nathalie Chugh, Jasveen Nott, Timothy J. Patel, Dony Spivey, Vicky L. Kettleborough, Catherine A. Bryans, Justin S. Taylor, Debra L. Smerdon, Stephen J. Buxton, Roger S. |
author_facet | Lougheed, Kathryn E.A. Osborne, Simon A. Saxty, Barbara Whalley, David Chapman, Tim Bouloc, Nathalie Chugh, Jasveen Nott, Timothy J. Patel, Dony Spivey, Vicky L. Kettleborough, Catherine A. Bryans, Justin S. Taylor, Debra L. Smerdon, Stephen J. Buxton, Roger S. |
author_sort | Lougheed, Kathryn E.A. |
collection | PubMed |
description | PknB is an essential serine/threonine kinase of Mycobacterium tuberculosis with possible roles in a number of signalling pathways involved in cell division and metabolism. We screened a library of >50,000 compounds for inhibitors of the in vitro phosphorylation of GarA (Rv1827) by PknB and identified a number of inhibitors. A program of synthetic medicinal chemistry was subsequently conducted around one class of inhibitors and was successful in generating ATP competitive inhibitors with potency in the nanomolar range. Compounds in this class showed cross-reactivity with the related M. tuberculosis kinase, PknF, but not with PknG in an in vitro autophosphorylation assay. These synthesised inhibitors were able to prevent the growth of M. tuberculosis in an Alamar blue assay and in an intracellular model of infection, but only in the micromolar range. We attempted to determine if cell wall permeability was an explanation for the discrepancy between the potent in vitro compared with relatively poor in vivo activity, but found no evidence that the activity of the inhibitors could be improved by weakening the cell wall. Despite a number of drug discovery efforts attempting to develop inhibitors against PknB, it is yet to be reported that any such inhibitors prevent mycobacterial growth at submicromolar concentrations. |
format | Online Article Text |
id | pubmed-3158675 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Churchill Livingstone |
record_format | MEDLINE/PubMed |
spelling | pubmed-31586752011-08-30 Effective inhibitors of the essential kinase PknB and their potential as anti-mycobacterial agents Lougheed, Kathryn E.A. Osborne, Simon A. Saxty, Barbara Whalley, David Chapman, Tim Bouloc, Nathalie Chugh, Jasveen Nott, Timothy J. Patel, Dony Spivey, Vicky L. Kettleborough, Catherine A. Bryans, Justin S. Taylor, Debra L. Smerdon, Stephen J. Buxton, Roger S. Tuberculosis (Edinb) Drug Discovery and Resistance PknB is an essential serine/threonine kinase of Mycobacterium tuberculosis with possible roles in a number of signalling pathways involved in cell division and metabolism. We screened a library of >50,000 compounds for inhibitors of the in vitro phosphorylation of GarA (Rv1827) by PknB and identified a number of inhibitors. A program of synthetic medicinal chemistry was subsequently conducted around one class of inhibitors and was successful in generating ATP competitive inhibitors with potency in the nanomolar range. Compounds in this class showed cross-reactivity with the related M. tuberculosis kinase, PknF, but not with PknG in an in vitro autophosphorylation assay. These synthesised inhibitors were able to prevent the growth of M. tuberculosis in an Alamar blue assay and in an intracellular model of infection, but only in the micromolar range. We attempted to determine if cell wall permeability was an explanation for the discrepancy between the potent in vitro compared with relatively poor in vivo activity, but found no evidence that the activity of the inhibitors could be improved by weakening the cell wall. Despite a number of drug discovery efforts attempting to develop inhibitors against PknB, it is yet to be reported that any such inhibitors prevent mycobacterial growth at submicromolar concentrations. Churchill Livingstone 2011-07 /pmc/articles/PMC3158675/ /pubmed/21482481 http://dx.doi.org/10.1016/j.tube.2011.03.005 Text en © 2011 Elsevier Ltd. https://creativecommons.org/licenses/by/3.0/ Open Access under CC BY 3.0 (https://creativecommons.org/licenses/by/3.0/) license |
spellingShingle | Drug Discovery and Resistance Lougheed, Kathryn E.A. Osborne, Simon A. Saxty, Barbara Whalley, David Chapman, Tim Bouloc, Nathalie Chugh, Jasveen Nott, Timothy J. Patel, Dony Spivey, Vicky L. Kettleborough, Catherine A. Bryans, Justin S. Taylor, Debra L. Smerdon, Stephen J. Buxton, Roger S. Effective inhibitors of the essential kinase PknB and their potential as anti-mycobacterial agents |
title | Effective inhibitors of the essential kinase PknB and their potential as anti-mycobacterial agents |
title_full | Effective inhibitors of the essential kinase PknB and their potential as anti-mycobacterial agents |
title_fullStr | Effective inhibitors of the essential kinase PknB and their potential as anti-mycobacterial agents |
title_full_unstemmed | Effective inhibitors of the essential kinase PknB and their potential as anti-mycobacterial agents |
title_short | Effective inhibitors of the essential kinase PknB and their potential as anti-mycobacterial agents |
title_sort | effective inhibitors of the essential kinase pknb and their potential as anti-mycobacterial agents |
topic | Drug Discovery and Resistance |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3158675/ https://www.ncbi.nlm.nih.gov/pubmed/21482481 http://dx.doi.org/10.1016/j.tube.2011.03.005 |
work_keys_str_mv | AT lougheedkathrynea effectiveinhibitorsoftheessentialkinasepknbandtheirpotentialasantimycobacterialagents AT osbornesimona effectiveinhibitorsoftheessentialkinasepknbandtheirpotentialasantimycobacterialagents AT saxtybarbara effectiveinhibitorsoftheessentialkinasepknbandtheirpotentialasantimycobacterialagents AT whalleydavid effectiveinhibitorsoftheessentialkinasepknbandtheirpotentialasantimycobacterialagents AT chapmantim effectiveinhibitorsoftheessentialkinasepknbandtheirpotentialasantimycobacterialagents AT boulocnathalie effectiveinhibitorsoftheessentialkinasepknbandtheirpotentialasantimycobacterialagents AT chughjasveen effectiveinhibitorsoftheessentialkinasepknbandtheirpotentialasantimycobacterialagents AT notttimothyj effectiveinhibitorsoftheessentialkinasepknbandtheirpotentialasantimycobacterialagents AT pateldony effectiveinhibitorsoftheessentialkinasepknbandtheirpotentialasantimycobacterialagents AT spiveyvickyl effectiveinhibitorsoftheessentialkinasepknbandtheirpotentialasantimycobacterialagents AT kettleboroughcatherinea effectiveinhibitorsoftheessentialkinasepknbandtheirpotentialasantimycobacterialagents AT bryansjustins effectiveinhibitorsoftheessentialkinasepknbandtheirpotentialasantimycobacterialagents AT taylordebral effectiveinhibitorsoftheessentialkinasepknbandtheirpotentialasantimycobacterialagents AT smerdonstephenj effectiveinhibitorsoftheessentialkinasepknbandtheirpotentialasantimycobacterialagents AT buxtonrogers effectiveinhibitorsoftheessentialkinasepknbandtheirpotentialasantimycobacterialagents |